Replies to post #121395 on Avid Bioservices Inc (CDMO)

[jakedogman1]

the only caveat is whether one arm is much different from an ecog status than the other. the pancreatic trial is a good example. seems to me that whoever is conducting the trial wants the data to be confusing in that the real answer is only understood by the insiders. mgmt went out of their way to downplay the significance of the panc trial results.

[DrRocker]

Thanks for the great explanation FTM. I appreciate your insights. You confirmed my suspicion that it is the separation between the two arms that matters. I am hopeful that the non-divergent independent reads on the PFS will not be a harbinger of a small separation in the MOS results.

[mojojojo]

I was looking at how the avastin plus paclitaxel and carboplatin 1st-line NSCLC trial finished up and it's final data was collected when 72.2% of the events were complete.

"median, 19 months; minimum time from study entry to the cutoff point for the primary analysis, 18 months"